Effect of nicorandil combined with rosuvastatin calcium in treatment of patients with slow coronary flow

FANG Zhiqin; LIANG Huiqing; ZHANG Pengxiang; ZHAO Kun; MA Yiping; WANG Yaling; LI Fangjiang; LI Jun; LI Pingping

doi:10.7619/jcmp.20241838

Journal of Clinical Medicine in Practice > 2024 > 28(15): 70-75. > DOI: 10.7619/jcmp.20241838

FANG Zhiqin, LIANG Huiqing, ZHANG Pengxiang, ZHAO Kun, MA Yiping, WANG Yaling, LI Fangjiang, LI Jun, LI Pingping. Effect of nicorandil combined with rosuvastatin calcium in treatment of patients with slow coronary flow[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 70-75. DOI: 10.7619/jcmp.20241838

Citation:

PDF (944 KB)

Effect of nicorandil combined with rosuvastatin calcium in treatment of patients with slow coronary flow

1.
Department of Cardiology, the First Hospital Affiliated to Hebei North University, Zhangjiakou, Hebei, 075000
2.
Department of Ultrasound Medicine, the First Hospital Affiliated to Hebei North University, Zhangjiakou, Hebei, 075000
3.
Department of Reproductive Medicine, the First Hospital Affiliated to Hebei North University, Zhangjiakou, Hebei, 075000

More Information

Received Date: May 05, 2024
Revised Date: June 19, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the effects of nicorandil combined with rosuvastatin calcium on monocyte-to-high density lipoprotein cholesterol ratio (MHR), systemic immune-inflammation index (SII), and cardiac function in patients with coronary slow flow (CSF).
Methods
A group case-control study was used to select 240 patients with CSF confirmed by coronary angiography, and they were randomly divided into observation group and control group, with 120 patients in each group. On the basis of conventional drug treatment, the control group was treated with rosuvastatin calcium, while the observation group was treated with nicorandil combined with rosuvastatin calcium for 6 months. Clinical efficacy, inflammatory markers[high-sensitivity C-reactive protein (hs-CRP), MHR, SII], corrected TIMI frame count (CTFC) of major coronary branches [left anterior descending branch (LAD), left circumflex branch (LCX), right coronary artery (RCA)], cardiac function indicators[left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), global longitudinal strain (GLS)], and the occurrence of major adverse cardiovascular events (MACE) were compared between the two groups.
Results
The total effective rate in the observation groupwas significantly higher than that in the control group (95.00% versus 80.00%, P < 0.05). After treatment, the duration, severity, andfrequency of angina pectoris attacks were reduced or shortened in both groups, with more changes observed in the observation group (P < 0.05). Serum levels of hs-CRP, MHR, and SII were lower in both groups after 6 months of treatment, and the observation group with significantly was lower compared to the control group (P < 0.05). CTFC values of LAD, LCX, and RCA were also lower in both groups after 6 months, with the observation group showing significantly lower values (P < 0.05). The absolute values of LVEF and GLS increased in both groups after 6 months of treatment, and the observation group was higher than the control group (P < 0.05). However, no significant difference was observed in LVEDD and occurrence of MACE between the two groups (P>0.05).
Conclusion
The application of nicorandil combined with rosuvastatin calcium in the treatment of CSF patients can significantly improve the overall treatment efficacy, reduce hs-CRP, MHR, and SII levels, enhance cardiac function indicators such as LVEF, LVEDD, and GLS, and effectively alleviate the severity of angina pectoris attacks.

FullText(HTML)

References (25)

References

[1]	KALAY N, KELEŞOGLU Ş. Coronary Slow Flow: a mysterious disease that has not yet been clarified[J]. Turk Kardiyol Dern Ars, 2023, 51(1): 1-2.
[2]	HUANG Q J, ZHANG F, CHEN S Y, et al. Clinical characteristics in patients with coronary slow flow phenomenon: a retrospective study[J]. Medicine, 2021, 100(6): e24643. doi: 10.1097/MD.0000000000024643
[3]	谭艳武. 尼可地尔治疗冠状动脉慢血流现象的临床效果与安全性[J]. 临床合理用药杂志, 2021, 14(17): 49-51. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202117020.htm
[4]	黄金龙, 冯晓秋. 冠状动脉慢血流的中西医研究进展[J]. 中医临床研究, 2021, 13(21): 38-40, 58. doi: 10.3969/j.issn.1674-7860.2021.21.015
[5]	张洪磊, 韦彩雯. 尼可地尔联合不同剂量瑞舒伐他汀钙片治疗冠状动脉慢血流的效果[J]. 西北药学杂志, 2024, 39(1): 191-196. doi: 10.3969/j.issn.1004-2407.2024.01.034
[6]	王艳. 尼可地尔联合双联抗血小板药物、瑞舒伐他汀对不稳定型心绞痛PCI术后心功能的影响[J]. 实用中西医结合临床, 2021, 21(5): 7-8. https://www.cnki.com.cn/Article/CJFDTOTAL-SZXL202105003.htm
[7]	郭艳娇, 张克成, 王丽杰, 等. 麝香保心丸联合尼可地尔对非阻塞性冠状动脉缺血疾病患者左室舒张功能的影响[J]. 辽宁中医杂志, 2023, 50(10): 139-142. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202310037.htm
[8]	MADDALI V R, NAGULA P, RAVI S, et al. Predictors of coronary slow flow phenomenon in patients with angina and normal epicardial coronaries[J]. Eur Heart J, 2021, 42(Supplement_1): ehab724. 1082. doi: 10.1093/eurheartj/ehab724.1082
[9]	朱雅男, 张志强, 朱云霞. 血清血管生成素样蛋白2及分泌型卷曲相关蛋白5预测急性冠状动脉综合征患者术后冠状动脉慢血流的价值[J]. 实用临床医药杂志, 2023, 27(3): 11-15, 20. doi: 10.7619/jcmp.20222734
[10]	李金佩, 王永槐, 李光源, 等. 冠状动脉慢血流相关危险因素的研究进展[J]. 实用临床医药杂志, 2022, 26(12): 115-118. doi: 10.7619/jcmp.20220353
[11]	ZHU Q, WANG S T, HUANG X, et al. Understanding the pathogenesis of coronary slow flow: recent advances[J]. Trends Cardiovasc Med, 2024, 34(3): 137-144. doi: 10.1016/j.tcm.2022.12.001
[12]	PATIL S, SARKAR A, PATIL M, et al. Evaluation of prevalence, clinical presentation and risk factors of coronary slow flow phenomenon: a single-center study[J]. Int J Res Med Sci, 2021, 9(4): 1106. doi: 10.18203/2320-6012.ijrms20211359
[13]	KARAUZUM K, KARAUZUM I, HANCI K, et al. The systemic immune-inflammation index may predict the coronary slow flow better than high-sensitivity C-reactive protein in patients undergoing elective coronary angiography[J]. Cardiol Res Pract, 2022, 2022: 7344639.
[14]	贺容容, 李锦霞, 任俊豪, 等. 单核细胞与高密度脂蛋白胆固醇比值在动脉粥样硬化性疾病中的研究进展[J]. 临床荟萃, 2022, 37(10): 950-952. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFC202210014.htm
[15]	刘洁良, 董豪坚. 尼可地尔对冠状动脉微循环障碍防治的研究进展[J]. 岭南心血管病杂志, 2022, 28(4): 375-378. https://www.cnki.com.cn/Article/CJFDTOTAL-LXGB202204019.htm
[16]	崔佳, 张明明, 王娜, 等. 糖脂代谢指标联合抗磷脂抗体对动脉粥样硬化患者预后的预测价值[J]. 实用医学杂志, 2024, 40(3): 326-329. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ202403008.htm
[17]	巨名飞, 刘超, 刘佳梅, 等. 急性冠状动脉综合征患者残余胆固醇水平与冠状动脉狭窄严重程度的相关性[J]. 实用医学杂志, 2023, 39(1): 71-75. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ202301012.htm
[18]	黎华, 黎静, 杨云飞, 等. 他汀类药物作用机制及临床应用进展[J]. 中国老年保健医学, 2023, 21(6): 116-119. https://www.cnki.com.cn/Article/CJFDTOTAL-LNBJ202306024.htm
[19]	彭宏伟, 张瑶瑶. 经皮冠状动脉介入术后冠状动脉慢血流治疗的研究进展[J]. 医学综述, 2021, 27(14): 2841-2845. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZS202114025.htm
[20]	冉碧霞. 瑞舒伐他汀与阿托伐他汀在老年冠心病治疗中的安全性分析[J]. 婚育与健康, 2024, 30(6): 55-57. https://www.cnki.com.cn/Article/CJFDTOTAL-HYJK202406019.htm
[21]	LEE S H, LEE Y J, HEO J H, et al. Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis[J]. J Am Coll Cardiol, 2023, 81(14): 1339-1349.
[22]	高杏, 尹璐瑶, 鲁洪涛, 等. 超声心动图评价冠状动脉慢血流现象的应用进展[J]. 现代生物医学进展, 2021, 21(23): 4598-4600, 4416. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202123042.htm
[23]	SHEREEF A S, ABDELMAJEED M G, ALSHAIR M H, et al. Coronary slow flow and its correlation with reduced left ventricle global longitudinal strain: a case-control study[J]. Echo Res Pract, 2024, 11(1): 2.
[24]	SEYYED-MOHAMMADZAD M H, RASHTCHIZADEH S, KHADEMVATANI K, et al. Ventricular dysfunction in patients with coronary slow-flow phenomenon: a single-center case-control study[J]. Heart Views, 2020, 21(2): 60-64.
[25]	朱洪涛. 尼可地尔对冠心病PCI术后冠脉慢血流及无复流的影响及远期预后分析[J]. 临床合理用药杂志, 2021, 14(34): 44-46. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202134019.htm

[1]	LI Xiaoyu, ZHANG Yongyong, QIN Juan, YANG Zhongxin. Changes of serological indexes and prognosis of acute coronary syndrome patients after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 60-62, 67. DOI: 10.7619/jcmp.20231532
[2]	LIU Yanqi, ZHENG Guanqun, CHEN Zhixian, JIN Xiaoqi, SHENG Xiaodong, WANG Zhiqiang. Correlation between plasma trimethylamine-N-oxide and coronary heart disease and its effect on the prognosis of patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 90-96. DOI: 10.7619/jcmp.20221667
[3]	LIANG Jing, HE Xueling, TANG Qian, TU Chongfang, QIAN Kun, LIU Hui. Relationships between red blood cell distribution width and in-stent restenosis as well as prognosis after percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2021, 25(21): 63-66, 73. DOI: 10.7619/jcmp.20213620
[4]	LI Jiancheng, XU Gangzheng. Value of hypersensitivity C-reactive protein in predicting the prognosis of coronary heart disease patients with interventional therapy[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 34-36. DOI: 10.7619/jcmp.202018009
[5]	LYU Jing, WANG Junhua. Correlation between plasma thrombomodulin level and early prognosis in patients with radial coronary artery bypass grafting[J]. Journal of Clinical Medicine in Practice, 2020, 24(18): 22-25. DOI: 10.7619/jcmp.202018006
[6]	SUN Huimin. Effect of rehabilitation nursing on postoperative recovery of coronary heart disease patients with percutaneous coronary intervention[J]. Journal of Clinical Medicine in Practice, 2019, 23(14): 56-58,79. DOI: 10.7619/jcmp.201914015
[7]	MENG Xiaofeng, SUI Shihua, SU Hao. Comparison in therapeutic effects and prognosis of interventional therapy in coronary heart disease patients with different blood glucose levels[J]. Journal of Clinical Medicine in Practice, 2016, (13): 1-4. DOI: 10.7619/jcmp.201613001
[8]	TU Xuemei. The effect and clinical analysis of continuous nursing intervention on prognosis of patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2015, (6): 4-6,22. DOI: 10.7619/jcmp.201506002
[9]	WANG Di. Relationship of hs-CRP with severity of coronary atherosclerosis and prognosis in coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2013, (15): 96-97,102. DOI: 10.7619/jcmp.201315035
[10]	ZHANG Ying, QIN Shu, ZHANG Dongyin, WANG Kechun. Relationship between high-sensitivity C-reactive protein and the severity and prognosis of coronary atherosclerosis of coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2012, (23): 45-48.

Cited By

Get Citation

PDF

XML

Article views PDF downloads

Turn off MathJax

Article Contents

Abstract

References

Effect of nicorandil combined with rosuvastatin calcium in treatment of patients with slow coronary flow

Abstract

References

Related Articles

Catalog

Effect of nicorandil combined with rosuvastatin calcium in treatment of patients with slow coronary flow

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content